Myconanotechnology: evaluation of Ag-Cu bimetallic nanoparticles synthesized by Ganoderma aff. australe against pathogens and cancer cells
Abstract
This study reports the biogenic synthesis of silver–copper (Ag/Cu) bimetallic nanoparticles using an aqueous extract of Ganoderma aff. australe collected in the State of Mexico. Taxonomic identification of the fungus was confirmed through basidiospore morphology. Mycochemical screening revealed the presence of alkaloids, flavonoids, reducing sugars, quinones, and coumarins in the extract, suggesting their involvement as reducing and stabilizing agents in nanoparticle formation. Structural characterization by UV–Vis, FTIR, SEM–EDS, and TEM confirmed the successful synthesis of quasi‑spherical Ag/Cu nanoparticles with an average diameter of 17.15 nm and a composition predominantly of copper (87.84%) with silver (12.16%). Antibacterial assays demonstrated promising inhibitory activity against both Gram‑positive (Staphylococcus aureus) and Gram‑negative (Escherichia coli) strains, with formulation M2‑3‑3 exhibiting the most consistent performance. Cytotoxicity assays (MTT) revealed selective anticancer activity of the nanoparticles, particularly against glioblastoma cell lines (A‑172 and U‑87 MG), while showing reduced cytotoxicity toward non‑cancerous fibroblasts (HDFn and Detroit 551). These findings highlight G. aff. australe‑mediated Ag/Cu nanoparticles as a sustainable and effective platform with dual antibacterial and anticancer potential. The study underscores the relevance of myconanotechnology for developing eco‑friendly nanomaterials with biomedical applications.
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.